(Family Features) Many people don’t think much about whether their blood is clotting properly. However, when you have a bleeding disorder, a condition that affects the way your body controls clots, it ...

Let’s be honest: Periods, in general, aren’t exactly comfortable. If you’re one of the 10 million Americans who deal with heavy bleeding during your period, then you have all the more reason to ...

Medically reviewed by Cordelia Nwankwo, MD Key Takeaways Bleeding between periods can be caused by stress, poor nutrition, or ...

COLLEGE STATION, Texas (KBTX) - The City of College Station recently recognized the month of March for National Bleeding Disorders Awareness Month, commending efforts of a Texas foundation that helps ...

Many people have a bleeding disorder and don't know it, but the Western Pennsylvania Bleeding Disorders Foundation is working to help people recognize the signs and get support. The foundation helps ...

ST. LOUIS – When it comes to bleeding disorders, most people immediately think of hemophilia. But there’s a wider range of conditions that can affect children, and they often go undetected. Dr. John ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

BioTek reMEDys has identified Bleeding Disorders Awareness Month (BDAM) as an opportunity to drive change, piggybacking on the national event to call for awareness of safe medication use in patients ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Pfizer Inc.’s gene therapy for a severe bleeding disorder met its goal in a pivotal late-stage trial, paving the way for the company to enter what’s proven to be a challenging market for drug ...

SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The treatment for ...